Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Nov 08, 2017
Genomic Health Announces Third Quarter 2017 Financial Results and Reports Recent Business Progress
Delivered 2 Percent Increase in Revenue; 5 Percent Increase in Test Volume
Reported Net Loss of $2.2M; Delivered $1.1M Profit on a Non-GAAP Basis
Announced Collaboration with Biocartis to Develop IVD Version of Oncotype DX Breast Cancer Test with a $3.2M Transaction Cost in the Third Quarter
Reiterates Full-year Revenue Guidance, Excluding Impact from Hurricane Disruption
Expects Full-year Profitability, Excluding Cost of Biocartis Transaction
Nov 01, 2017
Genomic Health to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017
REDWOOD CITY, Calif. , Nov. 1, 2017 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ:  GHDX ) today announced that the company will host a conference call and webcast on Wednesday, November 8 at 4:30 p.m. Eastern Time to discuss its third quarter 2017 financial results. The call and webcast will
Sep 13, 2017
Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access
Strategic Collaboration Aimed at Exclusive Test Development and Commercialization of Proprietary Genomic Health Tests on the Idylla™ Platform
Sep 11, 2017
Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017
New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast Cancer Do Not Have Aggressive Disease and Experience Excellent Five-year Survival without Chemotherapy
First Presentation of Distant Recurrence Data from German PlanB Study Shows Very Low Recurrence Rates at Five Years in Clinically High-risk Patients with Low Recurrence Score® Results and No Chemotherapy
Aug 31, 2017
Genomic Health Continues to Pioneer Genomic-based Cancer Diagnostics with Multiple Presentations at ESMO 2017 Congress
New Data Reinforce Unmatched Value of the Oncotype DX Breast Recurrence Score® Test to Examine Tumor Biology Across Patient Populations
Aug 30, 2017
Genomic Health to Present at the 2017 Wells Fargo Healthcare Conference
REDWOOD CITY, Calif. , Aug. 30, 2017 /PRNewswire/ --  Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 2017 Wells Fargo Healthcare Conference in Boston on Wednesday, September 6, 2017 at 9:05 a.m. Eastern Time . To access the live and subsequently archived webcast of
Aug 24, 2017
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® Genomic Prostate Score™ Test in Patients with Favorable Intermediate-risk Prostate Cancer Effective October 9, 2017
REDWOOD CITY, Calif. , Aug. 24, 2017 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) today announced that Palmetto GBA , a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a positive final Local Coverage Determination (LCD) to expand Medicare
Aug 01, 2017
Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress
Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue
Continued to Generate Strong Test Demand with 5 Percent Increase in U.S. Invasive Breast Cancer, 38 Percent Increase in U.S. Prostate and 12 Percent Increase in International Growth
Improved Earnings Per Share by $0.10
Company Adjusts 2017 Revenue Guidance; Expects Profit for the Full Year
Jul 20, 2017
Genomic Health to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017
REDWOOD CITY, Calif. , July 20, 2017 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, August 1 at 4:30 p.m. Eastern Time to discuss its second quarter 2017 financial results. The call and webcast will follow
Jul 12, 2017
Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role of Genomic Testing in Treatment of Early Breast Cancer
Oncotype DX® Test Endorsed for Guiding Treatment Decisions on Adjuvant Chemotherapy Both in Node-negative and in Node-positive Disease
Gene Expression Signatures Recommended for the First Time as Preferable to Standard Pathology When Adequate Reproducibility is Not Granted